Abstract:This study searched for relevant articles on the mechanism and clinical application of the ROS1 gene in recent years, systematically reviewed the biological mechanisms, diagnostic methods, and research progress on ROS1 inhibitors, and prospected the future of ROS1 targeted therapy to provide new ideas for clinical application and treatment. We believe that our study makes a significant contribution to the literature because our review revealed the following findings: the proto‐oncogene ROS1 is mostly expressed in malignant tumours, such as non‐small cell lung cancer (NSCLC). Only a few ROS1 kinase inhibitors are currently approved for use in NSCLC. At the same time, the efficacy of other tyrosine kinase inhibitors (TKIs) for NSCLC and other malignancies has not been ascertained as they are still being tested in clinical trials. There is no standard effective treatment for adverse events or resistance to ROS1‐targeted therapy. Finally, next‐generation TKIs appear capable of overcoming resistance and delaying central nervous system metastasis owing to their high affinity, but with a greater incidence of adverse effects. Background The proto‐oncogene ROS1 encodes an intrinsic type I membrane protein of the tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various malignancies via self‐mutations or rearrangements. Studies on ROS1‐directed tyrosine kinase inhibitors have been conducted, and some have been approved by the FDA for clinical use. However, the adverse effects and mechanisms of resistance associated with ROS1 inhibitors remain unknown. In addition, next‐generation ROS1 inhibitors, which have the advantage of treating central nervous system metastases and alleviating endogenous drug resistance, are still in the clinical trial stage. Method In this study, we searched relevant articles reporting the mechanism and clinical application of ROS1 in recent years; systematically reviewed the biological mechanisms, diagnostic methods, and research progress on ROS1 inhibitors; and provided perspectives for the future of ROS1‐targeted therapy. Results ROS1 is most expressed in malignant tumours. Only a few ROS1 kinase inhibitors are currently approved for use in NSCLC, the efficacy of other TKIs for NSCLC and other malignancies has not been ascertained. There is no effective standard treatment for adverse events or resistance to ROS1‐targeted therapy. Next‐generation TKIs appear capable of overcoming resistance and delaying central nervous system metastasis, but with a greater incidence of adverse effects. Conclusions Further research on next‐generation TKIs regarding the localization of ROS1 and its fusion partners, binding sites for targeted drugs, and coadministration with other drugs is required. The correlation between TKIs and chemotherapy or immunotherapy in clinical practice requires further study.

Thymic carcinomas and thymic neuroendocrine tumors: a tribute to Dr. Juan Rosai

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting

Lung Cancer with Concurrent EGFR Mutation and ROS1 Rearrangement: a Case Report and Review of the Literature

ROS in cancer therapy: the bright side of the moon

The Way Ahead: Lessons Learned from Decades of Cancer Research on Thymomas and Thymic Carcinomas

Clinical and translational implications of immunotherapy in sarcomas

Overall approaches to cardiac tumors: Still an unsolved enigma?

Mark Wick contributions to pathology of the mediastinum

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors

Spatial dissection of the immune landscape of solid tumors to advance precision medicine

Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)

Where We Are and Where We Will Go

Recent Noteworthy Studies in Thoracic Oncology

Approach to cardiac masses: Thinking inside and outside the box

Dr. Raymond Alexanian: Pioneering Contributions to Multiple Myeloma Research, Treatment, and the Concept of Curability

Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer

Thymoma: A Focus on Current Therapeutic Management

Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Multifocal Cutaneous Rosai-Dorfman Disease Treated With Localized Radiotherapy

Exploring the Therapeutic Frontiers